Inhaled budesonide for early treatment of COVID-19.

San-Juan, Rafael; Fernández-Ruiz, Mario; López-Medrano, Francisco; Aguado, José María

San-Juan, Rafael; Fernández-Ruiz, Mario; López-Medrano, Francisco; Aguado, José María.

San-Juan R; Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Hospital "12 de Octubre" (imas12), School of Medicine, Universidad Complutense, Madrid, 28041 Spain. Electronic address: rafasjg@yahoo.es.
Fernández-Ruiz M; Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Hospital "12 de Octubre" (imas12), School of Medicine, Universidad Complutense, Madrid, 28041 Spain.
López-Medrano F; Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Hospital "12 de Octubre" (imas12), School of Medicine, Universidad Complutense, Madrid, 28041 Spain.
Aguado JM; Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Hospital "12 de Octubre" (imas12), School of Medicine, Universidad Complutense, Madrid, 28041 Spain.

Lancet Respir Med ; 9(7): e58, 2021 07.

Article in English | MEDLINE | ID: covidwho-1337046

Subject(s)

Budesonide; COVID-19; Administration, Inhalation; Bronchodilator Agents/therapeutic use; Humans; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Budesonide / COVID-19 Limits: Humans Language: English Journal: Lancet Respir Med Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google